Novartis, Cephalon Disease-Modifying Parkinson’s Drugs Near Late Stages
Executive Summary
Novartis' and Cephalon's disease-modifying Parkinson's disease agents are approaching the final stages of development, with at least one pivotal trial slated to begin in 2004